CN100421666C - Epristeride slow release preparation - Google Patents
Epristeride slow release preparation Download PDFInfo
- Publication number
- CN100421666C CN100421666C CNB2006100412558A CN200610041255A CN100421666C CN 100421666 C CN100421666 C CN 100421666C CN B2006100412558 A CNB2006100412558 A CN B2006100412558A CN 200610041255 A CN200610041255 A CN 200610041255A CN 100421666 C CN100421666 C CN 100421666C
- Authority
- CN
- China
- Prior art keywords
- epristeride
- preparation
- slow
- release
- adjuvant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- VAPSMQAHNAZRKC-PQWRYPMOSA-N Epristeride Chemical compound C1C=C2C=C(C(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC2 VAPSMQAHNAZRKC-PQWRYPMOSA-N 0.000 title claims abstract description 32
- 229950009537 epristeride Drugs 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- 239000001856 Ethyl cellulose Substances 0.000 claims abstract description 9
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229920001249 ethyl cellulose Polymers 0.000 claims abstract description 9
- 235000019325 ethyl cellulose Nutrition 0.000 claims abstract description 9
- 239000002904 solvent Substances 0.000 claims abstract description 6
- 239000004925 Acrylic resin Substances 0.000 claims abstract description 5
- 239000000945 filler Substances 0.000 claims abstract description 4
- 239000000314 lubricant Substances 0.000 claims abstract description 4
- 239000000080 wetting agent Substances 0.000 claims abstract description 3
- 239000011248 coating agent Substances 0.000 claims description 12
- 238000000576 coating method Methods 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 8
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical class OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 6
- 239000003361 porogen Substances 0.000 claims description 4
- 229920002125 Sokalan® Polymers 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 30
- 230000000694 effects Effects 0.000 abstract description 8
- 239000008280 blood Substances 0.000 abstract description 6
- 210000004369 blood Anatomy 0.000 abstract description 6
- 239000003795 chemical substances by application Substances 0.000 abstract description 6
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract description 5
- 229920000609 methyl cellulose Polymers 0.000 abstract description 3
- 239000001923 methylcellulose Substances 0.000 abstract description 3
- 235000010981 methylcellulose Nutrition 0.000 abstract description 3
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 abstract 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 abstract 1
- 239000005977 Ethylene Substances 0.000 abstract 1
- 239000000853 adhesive Substances 0.000 abstract 1
- 230000001070 adhesive effect Effects 0.000 abstract 1
- 239000011148 porous material Substances 0.000 abstract 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 229940079593 drug Drugs 0.000 description 11
- 238000000034 method Methods 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 229960004756 ethanol Drugs 0.000 description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 5
- 239000008108 microcrystalline cellulose Substances 0.000 description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 210000002249 digestive system Anatomy 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 229960003473 androstanolone Drugs 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241001201614 Prays Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229950004422 hyetellose Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-N sodium;hydron;carbonate Chemical compound [Na+].OC(O)=O UIIMBOGNXHQVGW-UHFFFAOYSA-N 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention provides a kind of slow released epristeride preparation as 5alpha-reductase inhibiter for treating benign hyperplasia of prostate. The slow released epristeride preparation consists of epristeride 10-30 wt%, slow releasing supplementary material 30-60 wt%, and other supplementary material for the rest. The slow releasing supplementary material is hydropropyl methyl cellulose, ethyl cellulose, polyacrylate resin and/or polyhydroxy ethylene. The other supplementary material includes pore creating agent, filler, adhesive, lubricant, wetting agent, solvent and/or filming agent. The slow released epristeride preparation can maintain the blood medicine level for 24 hr and high curative effect.
Description
Technical field:
The present invention relates to a kind of pharmaceutical composition, particularly a kind of pharmaceutical composition that is used for the treatment of prostatic hyperplasia.
Background technology:
Epristeride (Epristeride); chemical name 17 β-(the N-tert-butyl group-amino-formoxyl) androstane-3; 5-diene-3-carboxylic acid; be a kind of optionally with noncompetitive steroid II type 5 inhibitor; reduce the content of dihydrotestosterone in the body of prostate by suppressing testosterone conversion dihydrotestosterone; cause outgrowth body of prostate atrophy, and the treatment benign prostate hyperplasia.
The epristeride sheet is to be gone on the market in exploitation in 1999 by Jiangsu Lianhuan Pharmaceutical Co., Ltd., is the tablet of ordinary preparation, oral administration.Epristeride is eliminated half-life (T
1/2β) be 7.5 hours, therefore, the epristeride sheet needs each 1 (5mg), and every day, each once to keep effective blood drug level in the body, reached the effect of treatment sooner or later.Epristeride is a kind of process of taking medicine for a long time, and in a single day this multiple dosing mode is made troubles not only for patient and doctor, and gone wrong in medication, then do not reach good curing.
At present the Chinese patent of relevant epristeride preparation has: 1, a kind of controlled release micro pill for the treatment of benign prostatic hyperplasia and preparation method (Granted publication number: CN1094347C, application number: 99117214.0); 2, epristeride drop pill and preparation method thereof (publication number: CN1562043A, application number: 200410030368.0).Slow releasing preparation does not need frequent drug administration, medicine can discharge on request lentamente at absorption site, the blood in human body in concentration is reached and remain in the effective concentration range, reduce side effects of pharmaceutical drugs and reduce administration frequency, compare with ordinary preparation, the safety and the advantages such as effectiveness and compliance of patients that improve medication are arranged.The present ordinary preparation that adopts, the time ratio of keeping effective blood drug concentration is shorter, all can not be above 12 hours.
Summary of the invention:
The objective of the invention is for the Epristeride slow release preparation of the concentration of remaining valid in a kind of 24 hours is provided.
For achieving the above object, technical scheme provided by the invention is achieved like this: Epristeride slow release preparation is characterized in that: by weight percentage said preparation contain following component:
Epristeride 10%-30%
Play the adjuvant 30%-60% of slow releasing function
Other adjuvant surplus
The adjuvant of above-mentioned slow releasing function is: hydroxypropyl methylcellulose, ethyl cellulose, polyacrylic resin class, carbopol apoplexy due to endogenous wind at least a; Described other adjuvant is a kind of in porogen, filler, binding agent, lubricant, wetting agent, solvent, the membrane material or several.
Porogen can adopt sucrose, mannitol, starch, Pulvis Talci etc.; Filler can adopt lactose, microcrystalline Cellulose etc.; Binding agent can adopt polyvinylpyrrolidone etc.; Lubricant can adopt stearic acid, magnesium stearate etc.; Membrane material can adopt polyvinyl alcohol, hydroxyl methylcellulose, hyetellose, methylcellulose etc.; Solvent can adopt dehydrated alcohol, ethanol, water etc.This preparation comprises the various preparations of the slow releasing preparation of film control, skeleton, gel, porous matrix type, also comprises making the various preparations that piller, microsphere or microcapsule etc. are made slow releasing preparation more earlier.Above-mentioned preparation formulation has tablet, capsule, coating type or other pharmaceutically common dosage form.The effect of slow releasing agent is to form the medicine barrier, the control medicine discharges lentamente at absorption site, the blood in human body in concentration is reached and remain in the effective concentration range, reduce side effects of pharmaceutical drugs and reduce administration frequency, the medicine peak value appears in the single administration blood drug level of can remaining valid in 24 hours about 12 hours; The present invention can be used for treating benign prostatic hyperplasia, can improve curative effect, reduces medicining times, reduces the incidence rate of side effect, takes easy to carry.
The specific embodiment:
Embodiment 1:
Epristeride slow release preparation contains following composition by weight percentage:
Epristeride 18.3%
Hydroxypropyl methylcellulose 56.4%
Microcrystalline Cellulose 21.8%
10% polyvinylpyrrolidone ethanol liquid 3%
Magnesium stearate 0.5%
Adopt the pharmaceuticals industry conventional method to make tablet or capsule, hydroxypropyl methylcellulose is a hydrophilic polymer, be framework material in said preparation, and expanding with water or Digestive system makes the gel barrier, controls the diffusion of epristeride, thereby reaches the purpose of slow release.
The mensuration of Epristeride slow release preparation cumulative release degree:
Get this product, according to dissolution method (two appendix XC first methods of Chinese Pharmacopoeia version in 2005), with 0.001mol/L caustic lye of soda 800ml is solvent, rotating speed is that per minute 80 changes, and operation was got dissolution fluid 5ml (adding the 5ml solvent simultaneously) in 1 hour respectively at 24 hours every intervals in accordance with the law, filter, get subsequent filtrate,, measure absorption value at 267nm wavelength place according to spectrophotography (two appendix IVA of Chinese Pharmacopoeia version in 2005); Other gets reference substance and is prepared into reference substance solution, measures the release that put computation time with method.The Epristeride slow release tablet of embodiment 1 preparation and the capsular cumulative release degree of the slow release 1-2 that sees the following form respectively:
The cumulative release degree of table 1 Epristeride slow release tablet
| Time (h) | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| Release (%) | 15 | 23 | 32 | 49 | 52 | 58 | 71 | 86 | 90 | 93 | 94 | 95 |
| Time (h) | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 |
| Release (%) | 97 | 98 | 97 | 94 | 94 | 93 | 90 | 88 | 87 | 86 | 83 | 83 |
The capsular cumulative release degree of table 2 Epristeride slow release
| Time (h) | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| Release (%) | 22 | 27 | 36 | 51 | 62 | 68 | 77 | 89 | 92 | 94 | 96 | 98 |
| Time (h) | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 |
| Release (%) | 98 | 98 | 96 | 95 | 93 | 90 | 87 | 89 | 84 | 83 | 81 | 81 |
Release is the average accumulated release in the table, and every of this product is more than 10%-30%, the 40%-70% and 75% of labelled amount 1,4,8 hour release respectively, all meets the medicine requirement, and drug level reaches peak value about 12 hours, descends gradually afterwards.
Embodiment 2:
Adopt the known method of pharmaceuticals industry to make slow releasing tablet (or capsule) and contain following composition by weight percentage:
Epristeride 25%
Ethyl cellulose 55.2%
Lactose 16.3%
3%HPMC ethanol liquid 3%
Magnesium stearate 0.5%
Ethyl cellulose is insoluble framework material, and medicine is dispersed in wherein, and the speed of drug release depends on diffusion velocity, slowly discharges from insoluble framework material, thereby reaches the purpose of slow release.Ethyl cellulose is treated to excrete after drug release fully.
Embodiment 3:
Adopt the known method of pharmaceuticals industry to make slow releasing tablet (or capsule) and contain following composition by weight percentage:
Epristeride 30%
Ethyl cellulose 30%
Stearic acid 23%
Lactose 11.5%
Ethyl cellulose anhydrous alcohol solution 4.5%
Magnesium stearate 1%
Stearic acid makes principal agent discharge slow releasing function gradually as the bioerodable material in vivo, and ethyl cellulose is not erodible framework material, treats to excrete after drug release fully.
Embodiment 4:
Adopt the known method of pharmaceuticals industry to make slow releasing tablet (or capsule) and contain following composition by weight percentage:
Epristeride 10%
Polyacrylic resin II 60%
Microcrystalline Cellulose 9%
Lactose 8%
Dehydrated alcohol 10%
10% polyvinylpyrrolidone ethanol liquid 2.5%
Magnesium stearate 0.5%
Polyacrylic resin is the undissolved polymer of intestinal, is coating material, and adding a spot of polyvinylpyrrolidone ethanol liquid in coating solution is porogen, i.e. solubilized in Digestive system, making on the clothing film has micropore, and medicine discharges from micropore, thereby prays slow releasing function.
Embodiment 5:
Adopt the known method of pharmaceuticals industry to make the agent of sustained release coating matrix and contain following composition by weight percentage:
Epristeride 28%
Microcrystalline Cellulose 50%
Polyvinylpyrrolidone 21.5%
Magnesium stearate 0.5%
Be the core more than for each component.As the further application of above medicine, can spray coating again on its surface, coating can prepare by following component:
Hydroxypropyl methylcellulose 35g
Propylene glycol 8g
Dodecyl sodium sulfate 0.5g
Pulvis Talci 2g
Water 100g
Be mixed and made into the coating aqueous suspension by above component.
Earlier piller is made in above-mentioned core, the coating aqueous suspension is sprayed on the core outer surface, and oven dry gets final product, and behind the oral administration, preparation is met water or Digestive system, and coating and corresponding hydrophilic polymer water absorption and swelling form the gel barrier, thereby has controlled the release of medicine.
Embodiment 6:
Adopt the known method of pharmaceuticals industry to make the agent of sustained release coating matrix and contain following composition by weight percentage:
Epristeride 25%
Microcrystalline Cellulose 54.5%
Carbopol 25%
Magnesium stearate 0.5%
It more than is each component core.
Cellulose acetate 75g
Hydroxypropyl methylcellulose 20g
Macrogol 4000 5.5g
Dichloromethane 1500ml
Methanol 750ml
It more than is each medicine coating solution.
Earlier the core is pressed into label, makes Cotton seeds with coating solution again, and then use laser boring.This preparation is in Digestive system, and hydrone enters the back medicine and forms certain osmotic pressure, makes the inside and outside pressure differential that forms of film, and the core itself of adding medicine has slow releasing function, can make medicine reach better slow release effect.
Claims (2)
1. Epristeride slow release preparation, said preparation contains following component by weight percentage:
Epristeride 10%-30%
Play the adjuvant 30%-60% of slow releasing function
Other adjuvant surplus
The adjuvant of above-mentioned slow releasing function is: hydroxypropyl methylcellulose, ethyl cellulose, polyacrylic resin class, carbopol apoplexy due to endogenous wind at least a; Described other adjuvant is a kind of in porogen, filler, binding agent, lubricant, wetting agent, solvent, the membrane material or several.
2. Epristeride slow release preparation according to claim 1 is characterized in that: the dosage form of preparation has sheet type, capsule-type, coating type.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100412558A CN100421666C (en) | 2006-07-27 | 2006-07-27 | Epristeride slow release preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100412558A CN100421666C (en) | 2006-07-27 | 2006-07-27 | Epristeride slow release preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1899290A CN1899290A (en) | 2007-01-24 |
| CN100421666C true CN100421666C (en) | 2008-10-01 |
Family
ID=37655400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100412558A Active CN100421666C (en) | 2006-07-27 | 2006-07-27 | Epristeride slow release preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100421666C (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101703510B (en) * | 2009-11-10 | 2014-06-25 | 沈阳药科大学 | Tamsulosin and finasteride compound sustained release tablets and preparation method thereof |
| CN101703511B (en) * | 2009-11-10 | 2014-10-29 | 沈阳药科大学 | Compound tamsulosin and finasteride sustained release capsule and preparation method thereof |
| CN102133180B (en) * | 2011-03-18 | 2016-03-09 | 黄芳 | A kind of long-acting injection preparation of sterides 5 alpha-reductase inhibitor and preparation method thereof |
| CN114931546A (en) * | 2022-04-20 | 2022-08-23 | 江苏联环药业股份有限公司 | Epipret external preparation for preventing and treating androgenetic alopecia |
| CN114917234A (en) * | 2022-04-22 | 2022-08-19 | 江苏联环药业股份有限公司 | Medicine for treating androgenetic alopecia |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1094347C (en) * | 1999-11-15 | 2002-11-20 | 广东药学院药物研究所 | A kind of controlled-release pellets for treating benign prostatic hyperplasia and preparation method thereof |
| CN1562043A (en) * | 2004-03-29 | 2005-01-12 | 南昌弘益科技有限公司 | Epristeride dripping pills and its preparing method |
-
2006
- 2006-07-27 CN CNB2006100412558A patent/CN100421666C/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1094347C (en) * | 1999-11-15 | 2002-11-20 | 广东药学院药物研究所 | A kind of controlled-release pellets for treating benign prostatic hyperplasia and preparation method thereof |
| CN1562043A (en) * | 2004-03-29 | 2005-01-12 | 南昌弘益科技有限公司 | Epristeride dripping pills and its preparing method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1899290A (en) | 2007-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102325526B (en) | Extend the pharmaceutical preparation of release | |
| EP0822809B1 (en) | Controlled release formulation for water soluble drugs in which a passageway is formed in situ | |
| KR100354644B1 (en) | Controlled Release Drug Delivery Device | |
| CN101987091B (en) | Venlafaxine hydrochloride sustained-release pellet capsules | |
| CN101478951A (en) | Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders | |
| CN100421666C (en) | Epristeride slow release preparation | |
| CN101637462B (en) | Compositions for conjugated estrogens and associated methods | |
| CN102026628A (en) | Oral controlled release tablet with reduced burst effect | |
| CN101002737A (en) | Slow release preparation of Kui-Liu-Ping | |
| CN101006989A (en) | Slow release preparation of alginic sodium diester | |
| CN106606490A (en) | Dapagliflozin tablet and preparation method thereof | |
| CN101636153A (en) | Time-specific delayed/pulsatile release dosage forms | |
| CN101099730A (en) | Oral solid preparation containing ambroxol hydrochloride and guaifenesin active components | |
| CN101015533A (en) | Sustained release preparation of norfloxacin | |
| CN101002745A (en) | Slow release preparation of cefdinir | |
| JP2024058686A (en) | Osmotic dosage forms containing deutetrabenazine and methods of use thereof | |
| CN100396282C (en) | Slow released doxazosin mesilate capsule and its prepn process | |
| CN109646417A (en) | A kind of Trimetazidine sustained release tablets and preparation method thereof | |
| CN101006990A (en) | Slow release preparation of cilostazol | |
| CN104706614B (en) | Tandospirone micropore permeation pump preparation | |
| CN101015530A (en) | Sustained release preparation of doxepin | |
| CN106619481A (en) | Long-acting 5-HT1A receptor stimulant and preparation method thereof | |
| CN101518519A (en) | Naringin slow-release tablet and method for preparing same | |
| CN101721380A (en) | Method for preparing sustained-release preparation | |
| CN106606489A (en) | Canagliflozin tablets and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP02 | Change in the address of a patent holder |
Address after: 225000 No.9, Jiankang 1st Road, biological health industrial park, Hanjiang District, Yangzhou City, Jiangsu Province Patentee after: JIANGSU LIANHUAN PHARMACEUTICAL Co.,Ltd. Address before: 225009 No. 21, Wenfeng Road, Yangzhou, Jiangsu Patentee before: JIANGSU LIANHUAN PHARMACEUTICAL Co.,Ltd. |
|
| CP02 | Change in the address of a patent holder |